Advanced Chemical Industries Limited

3rd Quarter ended Report 2020-2021 for the nine months period ended on 31 March 2021

Advanced Chemical Industries Limited Statement of financial position Unaudited

	Unaudited		
			gures in '000' Taka
	Note	As at 31 March 2021	As at 30 June 2020
	Note	51 March 2021	50 5une 2020
Assets		10-000 000-0000 0000-0000	
Property, plant and equipment	2	11,020,120	10,664,953
Right-of-use assets		514,859	499,940
Investments	3	3,066,203	2,950,640
Intangible assets		3,023	3,785
Biological assets		17,392	10,915
Deferred tax assets		361,407	214,067
Non-current assets '		14,983,004	14,344,301
Inventories	4	6,411,190	4,976,120
Trade receivables	5	3,357,983	3,881,479
Other receivables		623,589	374,563
Inter-company receivables	6	21,057,467	19,146,539
Advances, deposits and prepayments	7	860,686	743,851
Cash and cash equivalents		791,721	787,826
Current assets		33,102,636	29,910,379
Total assets		48,085,639	44,254,680
Equity		27	
Share capital	7	631,103	573,730
Share premium		402,310	402,310
Reserves		3,534,875	3,511,868
Retained earnings		12,303,555	10,933,326
Total equity		16,871,844	15,421,234
Liabilities			
Employee benefits	8	1,260,922	1,081,293
Long term borrowings	9	795,244	571,816
Non-current portion of lease liability		387,596	388,549
Non-current liabilities		2,443,762	2,041,658
Bank overdraft		3,270,285	2,502,963
Loans and borrowings	10	16,296,376	12,134,376
Current portion of lease liability		174,596	141,728
Trade payables		1,333,955	1,497,796
Inter-company payables	11	3,229,527	6,838,689
Other payables	12	3,716,219	3,133,616
Current tax liability		749,076	542,619
Current liabilities		28,770,034	26,791,787
Total liabilities		31,213,796	28,833,446
Total equity and liabilities		48,085,639	44,254,680

Net asset value (NAV) per share

J. Schma

244.35

267.34

Managing Director

Director

Chief Financial Officer

x2

Company Secretary

Advanced Chemical Industries Limited Statement of profit or loss Unaudited

				Figu	res in '000' Taka
		For the nine m	onths from	For the 3rd Q	uarter from
	Note	July 2020 to March 2021	July 2019 to March 2020	January 2021 to March 2021	January 2020 to March 2020
Revenue	13	19,556,207	17,257,345	5,961,991	5,971,519
Cost of sales	14	(10,818,769)	(8,877,019)	(3,324,771)	(3,050,569)
Gross profit		8,737,438	8,380,326	2,637,220	2,920,950
Administrative, selling and distribution expenses	15	(6,289,605)	(6,580,598)	(1,878,374)	(2,205,456)
Other income		476,197	476,212	11,662	14,552
Operating profit		2,924,029	2,275,940	770,508	730,046
Net finance costs		(225,773)	(544,511)	(45,315)	(194,876)
Profit before contribution to WPPF		2,698,256	1,731,429	725,192	535,170
Contribution to WPPF		(134,913)	(86,571)	(36,260)	(26,758)
Profit before tax		2,563,343	1,644,858	688,933	508,411
Income tax expense		(676,757)	(432,059)	(189,975)	(133,534)
Profit after tax		1,886,586	1,212,798	498,958	374,877

Earnings per share Basic and diluted earnings per share (EPS)

29.89

19.22

7.91

0 1. R a

Managing Director

Director

Chief Financial Officer

/company Secretary

5.94

	For the nine	months from	Figures in '000' Ta For the 3rd Quarter from		
	July 2020 to March 2021	to to to		January 2020 to March 2020	
Profit after tax	1,886,586	1,212,798	498,958	374,877	
Other comprehensive income:					
Change in fair value of FVOCI financial assets	25,563	(121,992)	-	(38,186)	
Income tax on FVOCI financial assets	(2,556)	12,199	-	3,818	
Other comprehensive income, net of tax	23,007	(109,793)	-	(34,368)	
Total comprehensive income	1,909,593	1,103,005	498,958	340,509	

Advanced Chemical Industries Limited Statement of profit or loss and other comprehensive income Unaudited

Advanced Chemical Industries Limited Statement of changes in equity Unaudited

Figures in '000' Taka

				For th	e nine months fi	rom July 2020 to	March 2021
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity
Balance at 1 July 2020	573,730	402,310	1,671	434,656	3,075,541	10,933,326	15,421,234
Total comprehensive income							
Profit after tax	-	-	-	-	-	1,886,586	1,886,586
Other comprehensive income-net of tax	-	-	-	23,007	-	-	23,007
Total comprehensive income	-	-	-	23,007	-	1,886,586	1,909,593
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	-
Stock dividend for 2019-20	57,373	-	-	-	-	(57,373)	-
Cash dividend for 2019-20	-	-	-	-	-	(458,984)	(458,984)
Total transactions with owners of the Company	57,373	-	-	-	-	(516,357)	(458,984)
Balance at 31 March 2021	631,103	402,310	1,671	457,663	3,075,541	12,303,555	16,871,844

	For the nine months from July 2019 to March 2						
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity
Balance at 1 July 2019	498,895	402,310	1,671	555,904	3,075,541	9,788,136	14,322,458
Total comprehensive income							
Profit after tax	-	-	-	-	-	1,212,798	1,212,798
Other comprehensive income-net of tax	-	-	-	(109,793)	-	-	(109,793)
Total comprehensive income	-	-	-	(109,793)	-	1,212,798	1,103,005
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	-
Stock dividend 2018-19	74,834	-	-	-	-	(74,834)	-
Cash dividend for 2018-19	-	-	-	-	-	(498,895)	(498,895)
Total transactions with owners of the Company	74,834	-	-	-	-	(573,730)	(498,895)
Balance at 31 March 2020	573,730	402,310	1,671	446,111	3,075,541	10,427,206	14,926,569

Advanced Chemical Industries Limited Statement of cash flows Unaudited

		gures in '000' Taka
	For the nine	
	July 2020	July 2019
	to	to
	March 2021	March 2020
Cash flows from operating activities		
Cash receipts from customers and others	19,521,247	17,764,137
Cash paid to suppliers and employees	(17,291,835)	(13,969,583)
Cash generated from operating activities	2,229,412	3,794,554
Paid to WPPF	(88,560)	(40,378)
Finance costs paid	(190,664)	(461,968)
Income tax paid	(620,197)	(370,194)
	(899,421)	(872,540)
Net cash from / (used in) operating activities* 16	1,329,991	2,922,014
	, ,	, ,
Cash flows from investing activities		
Acquisition of property, plant and equipment	(170,337)	(183,140)
Payments for capital work in progress	(548,485)	(828,756)
Sale proceeds from property, plant and equipment	4,346	5,429
Purchase of biological assets	(6,548)	-
Dividend received	442,728	386,787
Investment	(90,000)	(297,097)
Net cash from / (used in) investing activities	(368,297)	(916,777)
Cash flows from financing activities		
Inter-company debts received/(paid)	(5,520,089)	(3,247,824)
Dividend paid	(471,180)	(63,474)
Payment for lease liabilities	(119,281)	(129,632)
Short-term bank loan received/(paid)	4,110,967	832,181
Long-term bank loan received/(paid)	274,461	9,322
Net cash from / (used in) financing activities	(1,725,122)	(2,599,427)
Net increase / (decrease) in cash and cash equivalents	(763,427)	(594,188)
Cash and cash equivalents at 1 July	(1,715,137)	(1,640,288)
Cash and cash equivalents at 31 March	(2,478,564)	(2,234,476)
Closing balance represents		
Cash and cash equivalents	791,721	921,194
Bank overdraft	(3,270,285)	(3,155,670)
	(2,478,564)	(2,234,476)
Net operating cash flows per share (NOCFPS)	21.07	46.30

*See Note 16 for reconciliation of net operating cash flow.

U	naudited		gures in '000' Taka				
		Fi					
		As at	As at				
	Note	31 March 2021	30 June 2020				
Assets							
Property, plant and equipment	2 (a)	26,788,171	26,682,431				
Right-of-use assets		1,548,434	1,505,563				
Equity-accounted investees		1,736,610	1,668,822				
Other investments		811,919	777,345				
Intangible assets		99,347	115,683				
Biological assets		17,392	10,915				
Deferred tax assets		675,947	398,907				
Non-current assets		31,677,820	31,159,665				
, ,	4 (a)	17 426 690	12 545 672				
Inventories	4 (a)	17,436,689	12,545,672				
Trade receivables	5 (a)	12,222,815	12,212,919				
Other receivables		1,010,750	670,119				
Inter-company receivables	6 (a)	9,591	9,525				
Advances, deposits and prepayments	7 (a)	2,679,944	2,082,002				
Short term investments		1,142,940	1,070,000				
Cash and cash equivalents		3,281,944	1,812,922				
Current assets		37,784,673	<u> </u>				
Total assets		69,462,493	01,502,625				
Equity		e					
Share capital		631,103	573,730				
Share premium	0	928,707	402,310				
Reserves		4,734,452	4,711,255				
Retained earnings		1,619,766	2,211,343				
Equity attributable to the owners of the Company		7,914,028	7,898,638				
Non-controlling interest		291,694	(608,661				
Total equity		8,205,722	7,289,977				
Liabilities	0()	1 500 251	1 2 (7 010				
Employee benefits	8 (a)	1,592,351	1,367,018				
Long term borrowings	9 (a)	8,438,863	8,271,768				
Non-current portion of lease liability		1,233,699	1,180,585				
Non-current liabilities		11,264,913	10,819,371				
Bank overdraft		5,181,155	4,440,894				
Loans and borrowings	10 (a)	32,790,974	27,288,288				
Current portion of lease liability		442,490	402,088				
Trade payables	ananatana data man	4,308,345	4,897,372				
Other payables	12 (a)	6,847,297	6,089,293				
Current tax liability		421,596	335,539				
Current liabilities		49,991,857	43,453,475				
Total liabilities		.61,256,770	54,272,846				
Total equity and liabilities		69,462,493	61,562,823				
	10	125 40	135 16				

Advanced Chemical Industries Limited Consolidated statement of financial position Unaudited

Net asset value (NAV) per share

Managing Director

Director

110

Chief Financial Officer

2

125.40

/company Secretary

125.16

6

. Lak

18

Advanced Chemical Industries Limited Consolidated statement of profit or loss Unaudited

	14099			Figu	res in '000' Taka
		For the nine	months from	For the 3rd Q	uarter from
	Note	July 2020 to March 2021	July 2019 to March 2020	January 2021 to March 2021	January 2020 to March 2020
Revenue	13 (a)	56,969,655	51,859,146	19,591,325	18,405,542
Cost of sales	14 (a)	(41,150,999)	(36,227,875)	(14,471,945)	(12,807,157)
Gross profit		15,818,656	15,631,271	5,119,380	5,598,385
Administrative, selling and distribution expenses	15 (a)	(12,068,984)	(12,641,582)	(3,886,251)	(4,401,898)
Other income / (loss)	. ,	269,167	206,162	78,809	74,195
Operating profit Share of the profit of equity accounted investees		4,018,840 360,063	3,195,851 209,033	1,311,938 108,399	1,270,682 38,744
Net finance costs		(2,653,064)	(3,525,661)	(859,410)	(1,296,496)
Profit/ (loss) before contribution to WPPF		1,725,839	(120,777)	560,927	12,930
Contribution to WPPF		(216,979)	(164,900)	(63,144)	(53,777)
Profit/ (loss) before tax		1,508,860	(285,676)	497,783	(40,847)
Income tax expense		(1,347,627)	(909,458)	(496,550)	(335,493)
Profit/ (loss) after tax		161,233	(1,195,134)	1,233	(376,340)
Profit/ (loss) attributable to:					
Equity holders of the company		223,146	(1,003,320)	21,887	(303,609)
Non-controlling interests		(61,913)	(191,815)	(20,654)	(72,731)
Profit/ (loss) after tax		161,233	(1,195,134)	1,233	(376,340)
Earnings per share					
Basic and diluted earnings per share (EPS)	18	3.54	(15.90)	0.35	(4.81)

Managing Director

Director

•

0

Company Secretary

Chief Financial Officer

23

	Unaudited	•		
	For the nine m	onths from	Figu For the 3rd Q	res in '000' Taka Quarter from
	July 2020 to March 2021	July 2019 to March 2020	January 2021 to March 2021	January 2020 to March 2020
Profit/ (loss) after tax	161,233	(1,195,134)	1,233	(376,340)
Other comprehensive income:				
Foreign operations - foreign currency translation differences	-	(493)	233	(63)
Change in fair value of FVOCI financial assets	25,806	(122,507)	(272)	(38,186)
Income tax on other comprehensive income	(2,581)	12,251	27	3,818
Other comprehensive income, net of tax	23,225	(110,750)	(11)	(34,430)
Total comprehensive income	184,458	(1,305,884)	1,221	(410,770)
Total comprehensive income attributable to:				
Equity holders of the Company				
Profit/ (loss) after tax	223,146	(1,003,320)	21,887	(303,609)
Other comprehensive income	23,198 246,344	(110,657) (1,113,976)	(21) 21,865	(34,426) (338,035)
Non controlling interest	,.	(1,-20,2,-2)	,	(***,***)
Non-controlling interest Profit/ (loss) after tax	(61,913)	(191,815)	(20,654)	(72,731)
Other comprehensive income	(01,913)	(191,813) (93)	(20,034)	(72,731) (4)
	(61,886)	(191,908)	(20,644)	(72,735)
Total comprehensive income	184,458	(1,305,884)	1,221	(410,770)

Advanced Chemical Industries Limited Consolidated statement of profit or loss and other comprehensive income

Advanced Chemical Industries Limited Consolidated Statement of changes in equity Unaudited

Figures in '000' Taka

For the nine months from July 2020 to March 2021

		Attributable to owners of the Company								
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2020	573,730	402,310	1,671	(1,397)	433,047	4,277,934	2,211,343	7,898,638	(608,661)	7,289,977
Total comprehensive income										
Profit/ (loss) after tax	-	-	-	-	-	-	223,146	223,146	(61,913)	161,233
Other comprehensive income-net of tax	-		-	-	23,197	-	-	23,197	28	23,225
Total comprehensive income	-	-	-	-	23,197	-	223,146	246,343	(61,885)	184,458
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend for 2019-20	57,373	-	-	-	-	-	(57,373)	-	-	-
Cash dividend for 2019-20	-	-	-	-	-	-	(458,984)	(458,984)	(41,868)	(500,851)
Effect of issuing new shares to Bangladesh Managed Account C.V. (a										
limited partnership of FMO) by ACI Motors Ltd.	-	526,397	-	-	-	-	(298,367)	228,030	770,774	998,805
Capital contribution by non-controlling interest (BMA C.V.)	-	-	-	-	-	-	-	-	233,333	233,333
Total transactions with owners of the Company	57,373	526,397	-	-	-	-	(814,723)	(230,953)	962,240	731,287
Balance at 31 March 2021	631,103	928,707	1,671	(1,397)	456,244	4,277,934	1,619,766	7,914,028	291,694	8,205,722

For the nine months from July 2019 to March 2020

	Attributable to owners of the Company									
	Share	Share	Capital	Translation	Available for	Revaluation	Retained	-	Non-controlling	Total
	capital	premium	reserve	reserve	sale reserve	surplus	earnings	Total	Interests	equity
Balance at 1 July 2019	498,895	402,310	1,671	(848)	554,781	4,277,934	3,845,275	9,580,018	(351,284)	9,228,734
Total comprehensive income										
Profit/ (loss) after tax	-	-	-	-	-	-	(1,003,320)	(1,003,320)	(191,815)	(1,195,134)
Other comprehensive income-net of tax	-	-	-	(459)	(110,198)	-	-	(110,657)	(93)	(110,749)
Total comprehensive income	-	-	-	(459)	(110,198)	-	(1,003,320)	(1,113,976)	(191,908)	(1,305,884)
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend 2018-19	74,834	-	-	-	-	-	(74,834)	-	-	-
Cash dividend for 2018-19	-	-	-	-	-	-	(498,895)	(498,895)	(73,269)	(572,164)
Adjustment for transfer of shares in subsidiary	-	-	-	-	-	-	(25)	(25)	57,378	57,353
Total transactions with owners of the Company	74,834	-	-	-	-	-	(573,755)	(498,920)	(15,891)	(514,811)
Balance at 31 March 2020	573,730	402,310	1,671	(1,307)	444,583	4,277,934	2,268,201	7,967,122	(559,083)	7,408,039

Advanced Chemical Industries Limited Consolidated statement of cash flows Unaudited

		Figu	res in '000' Taka			
		For the nine months from				
		July 2020	July 2019			
		to	to			
		March 2021	March 2020			
Cash flows from operating activities		56 450 126	52 024 615			
Cash receipts from customers and others		56,450,136	52,034,615			
Cash paid to suppliers and employees		(56,595,167)	(48,472,652)			
Cash generated from operating activities		(145,031)	3,561,962			
Paid to WPPF		(151,488)	(76,289)			
Finance costs paid		(1,997,965)	(2,823,435)			
Income tax paid		(1,541,192)	(1,118,220)			
		(3,690,645)	(4,017,944)			
Net cash from / (used in) operating activities *	16 (a)	(3,835,675)	(455,981)			
Cash flows from investing activities						
Acquisition of property, plant and equipment		(505,661)	(717,815)			
Payments for capital work in progress		(761,638)	(1,191,311)			
Sale proceeds from property, plant and equipment		4,966	5,429			
Purchase of biological assets		(6,548)	-			
Dividend received		394,595	302,556			
Short term investments		(72,940)	(1,070,000)			
Long term investments		(91,876)	(297,060)			
Net cash from / (used in) investing activities		(1,039,102)	(2,968,201)			
Cash flows from financing activities						
Inter-company debts received/(paid)		(66)	(41,174)			
Dividend paid		(471,180)	(63,474)			
Payment for lease liabilities		(313,452)	(341,692)			
Dividend paid to non-controlling interest		(41,443)	(67,291)			
Equity investment received by ACI Motors Limited		1,232,138	-			
Short-term bank loan received/(paid)		7,052,688	2,521,844			
Long-term bank loan received/(paid)		(1,855,254)	185,820			
Net cash from / (used in) financing activities		5,603,430	2,194,034			
Net increase / (decrease) in cash and cash equivalents		728,652	(1,230,149)			
Cash and cash equivalents at 1 July		(2,627,972)	(2,298,189)			
Effect of movements in exchange rates on cash held		108	91			
Cash and cash equivalents at 31 March		(1,899,212)	(3,528,247)			
Closing balance represents						
Cash and cash equivalents		3,281,944	1,840,654			
Bank overdraft		(5,181,155)	(5,368,901)			
		(1,899,212)	(3,528,247)			
Net operating cash flows per share (NOCFPS)	18	(60.78)	(7.23)			

*See Note 16(a) for reconciliation of consolidated net operating cash flow.

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2019 to 30 June 2020. This interim financial report includes only those selected explanatory notes as deemed appropriate for better understanding of unaudited financial statements.

2	Property, plant and equipment	Fig 31 March 2021 	Figures in '000' Taka 30 June 2020 Taka		
	Opening balance	12,626,796	11,352,682		
	Additions	718,822	1,284,480		
	Disposals	(4,389)	(10,365)		
	Accumulated depreciation	(2,321,109)	(1,961,843)		
	Closing balance	11,020,120	10,664,953		
2 (a)	Consolidated property, plant and equipment				
	Opening balance	32,255,436	29,600,056		
	Additions	1,267,569	2,666,697		
	Disposals	(6,630)	(11,317)		
	Accumulated depreciation	(6,728,204)	(5,573,006)		
	Closing balance	26,788,171	26,682,431		
3	Investments				
	Investment in subsidiaries	1,751,736	1,751,736		
	Investment in joint ventures	510,000	510,000		
	Investment in associates	467,548	377,548		
	Investment in shares	539,969	514,406		
	Investment in FDR/ other deposits	70,550	70,550		
	Impairment	(273,600)	(273,600)		
		3,066,203	2,950,640		
4	Inventories				
	Raw materials	2,490,702	1,524,251		
	Packing materials	655,356	531,724		
	Work-in-process	207,535	206,515		
	Finished goods	3,237,094	2,555,273		
	Goods in transit	415,272	533,457		
	Stores and spares	79,286	69,402		
	Allowance for inventory	(674,055)	(444,500)		
		6,411,190	4,976,120		

		Figu 31 March 2021 Taka	ures in '000' Taka 30 June 2020 Taka
4 (a)	Consolidated inventories		
	Raw materials	5,074,186	3,315,790
	Packing materials	723,263	585,905
	Work-in-process	414,933	345,348
	Finished goods	10,366,773	7,649,100
	Goods in transit	1,591,131	1,112,551
	Stores & spares	233,540	205,311
	Allowance for inventory	(967,136)	(668,334)
		17,436,689	12,545,672
5	Trade receivables		
	Debts due over six months	2,539,813	3,042,260
	Debts due below six months	1,620,180	1,423,802
	Provision for doubtful debts	(802,010)	(584,583)
		3,357,983	3,881,479
5 (a)	Consolidated trade receivables		
	Debts due over six months	4,619,850	4,696,631
	Debts due below six months	8,829,393	8,503,579
	Provision for doubtful debts	(1,226,428)	(987,291)
		12,222,815	12,212,919
6	Inter-company receivables		
	ACI Logistics Limited	7,193,689	6,238,282
	ACI HealthCare Limited	5,667,441	4,737,689
	ACI Foods Limited	2,863,389	2,883,554
	Premiaflex Plastics Limited	2,630,109	2,463,634
	ACI Formulations Limited	521,177	865,637
	ACI Biotech Limited	856,516	788,595
	ACI Agrolink Limited	692,622	633,046
	Infolytx Bangladesh Limited	417,310	335,374
	ACI Chemicals Limited	205,624	188,194
	Asian Consumer Care (Pvt.) Limited	7,894	7,894
	ACI Godrej Agrovet (Pvt.) Limited	939	939
	Tetley ACI (Bangladesh) Limited	576	546
	Stochastic Logic Limited	152	116
	Computer Technology Limited	30	30
	Creative Communication Limited	-	3,009
		21,057,467	19,146,539

		Fig 31 March 2021 Taka	igures in '000' Taka 30 June 2020 Taka	
6 (a)	Consolidated inter-company receivables			
	Computer Technology Limited	30	30	
	Tetley ACI (Bangladesh) Limited	576	546	
	Asian Consumer Care (Pvt.) Limited	7,894	7,894	
	ACI Godrej Agrovet (Pvt.) Limited	939	939	
	Stochastic Logic Limited	152	116	
		9,591	9,525	
7	Advances, deposits & prepayments			
	Advances to staff, suppliers and others	209,037	257,756	
	VAT current account	363,612	240,320	
	Deposits	220,934	215,925	
	Prepayments	67,103	29,850	
		860,686	743,851	
7 (a)	Consolidated advances, deposits & prepayments			
	Advances to staff, suppliers and others	1,109,004	1,079,057	
	VAT current account	833,179	371,963	
	Advance for capital expenditure	1,160	9,241	
	Deposits	419,676	388,571	
	Prepayments	316,925	233,170	
		2,679,944	2,082,002	
8	Employee benefits			
	Staff gratuity provision	1,072,083	932,887	
	Other long term employee benefits	188,839	148,405	
		1,260,922	1,081,293	
8 (a)	Consolidated employee benefits			
	Staff gratuity provision	1,322,604	1,152,626	
	Other long term employee benefits	269,747	214,392	
		1,592,351	1,367,018	

		Fig 31 March 2021 Taka	Figures in '000' Taka 30 June 2020 Taka	
9	Long term borrowings			
	Long term bank loans	795,244	571,816	
		795,244	571,816	
9 (a)	Consolidated long term borrowings			
	Long term bank loans	8,438,863	8,271,768	
		8,438,863	8,271,768	
10	Loans and borrowings - short term			
	Short term loan	16,017,938	11,906,971	
	Current portion of long term loan	278,438	227,405	
		16,296,376	12,134,376	
10 (a)	Consolidated loans and borrowings - short term			
	Short term loan	29,861,751	22,822,007	
	Current portion of long term loan	2,929,223	4,466,281	
		32,790,974	27,288,288	
11	Inter company payables			
	ACI Marine and Riverine Technologies Limited	39,582	12,187	
	ACI Motors Limited	993,056	4,923,968	
	ACI Salt Limited	1,365,916	1,294,346	
	ACI Pure Flour Limited	711,123	553,167	
	ACI Edible Oils Limited	69,475	55,021	
	Creative Communication Limited	50,375	-	
		3,229,527	6,838,689	

		Fig 31 March 2021 Taka	gures in '000' Taka 30 June 2020 Taka
12	Other payables		
	Accruals	2,235,635	1,689,212
	Advance from customers	111,875	140,664
	Security money received from customers	49,608	75,841
	Workers' profit participation fund	689,497	608,200
	Dividend payable	148,754	160,951
	Tax and VAT deducted at source	92,541	113,637
	Employees welfare fund	306,981	262,054
	Rights share deposit to be refunded	564	564
	Family day fund	5,317	4,837
	Non-management staff provident fund	6,050	6,817
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
	Payable for redemption of Zero Coupon Bonds	20,403	20,403
	Management staff provident fund	13,473	20,894
	Advertisement and promotional funds	20,595	17,736
	Development funds	11,280	8,159
		3,716,219	3,133,616
12 (a)	Consolidated other payables		
	Accruals	4,636,418	3,819,443
	Advance from customers	391,003	565,444
	Security money received from customers	102,337	127,570
	Workers' profit participation fund	907,122	796,687
	Dividend payable	161,759	173,531
	Provident fund	13,473	20,894
	Tax and VAT deducted at source	238,349	233,834
	Employees welfare fund	321,840	282,585
	Rights share deposit to be refunded	564	564
	Family day fund	5,317	4,837
	Non-management staff provident fund	6,050	6,817
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
	Payable for redemption of Zero Coupon Bonds	20,403	20,403
	Creditors for capital expenditure	7,141	7,141
	Advertisement and promotional funds	20,595	17,736
	Development funds	11,280	8,159
		6,847,297	6,089,293

		Figures in '000' Tak For the nine months from				
		July 2020	July 2019			
		to	to			
		March 2021	March 2020			
		Taka	Taka			
13	Revenue					
	Pharmaceuticals	9,036,782	8,852,918			
	Animal health	3,259,198	2,702,368			
	Consumer brands	5,432,817	4,013,079			
	Seeds	913,954	906,218			
	Fertilizer	797,062	727,281			
	Animal genetics and others	116,394	55,481			
		19,556,207	17,257,345			
13 (a)	Consolidated revenue					
	Gross sales	58,247,650	52,701,753			
	Inter-company sales	(1,277,995) 56,969,655	(842,608) 51,859,146			
		50,707,055	51,059,110			
14	Cost of sales					
	Opening stock	4,817,762	5,508,860			
	Purchase	10,897,004	8,095,389			
		15,714,766	13,604,250			
	Closing stock	(6,590,687)	(5,739,326)			
		9,124,080	7,864,924			
	Manufacturing expenses	1,694,690	1,012,095			
		10,818,769	8,877,019			
14 (a)	Consolidated cost of sales					
	Opening stock	11,902,574	12,237,772			
	Purchase	42,902,395	35,526,716			
		54,804,969	47,764,488			
	Closing stock	(16,585,584)	(14,110,517)			
	¥	38,219,384	33,653,971			
	Manufacturing expenses	2,931,614	2,573,904			
		41,150,999	36,227,875			
15	Administrative, selling and distribution expenses					
	Administrative expenses	289,164	320,391			
	Distribution expenses	745,390	663,833			
	Selling expenses	5,255,051	5,596,374			
	Sound expenses	6,289,605	6,580,598			
		0,209,003	0,500,590			

		Figures in '000' Taka For the nine months from				
		July 2020 to March 2021 Taka	July 2019 to March 2020 Taka			
15 (a)	Consolidated operating expenses	Taka	1 axa			
	Administrative expenses	2,128,583	2,110,777			
	Distribution expenses	1,480,350	1,329,269			
	Selling expenses	8,460,052	9,201,536			
_		12,068,984	12,641,582			
16	Reconciliation of net operating cash flow					
	Profit after tax	1,886,586	1,212,798			
	Adjustment for non-cash items and others:					
	- Depreciation and amoritisation	361,913	377,089			
	- Provisions	446,982	508,930			
	- Finance cost	35,109	82,543			
	- Tax Expense	56,560	61,865			
	- Contribution to WPPF	46,352	46,193			
	-Lease and other adjustments	117,102	93,293			
	Changes in:					
	- Inventories	(1,664,625)	(97,134)			
	- Trade and other receivables	(385,684)	115,267			
	- Advances, deposits and prepayments	(100,058)	(49,965)			
	- Trade and other payables, employment benefits	529,754	571,134			
	Net cash from operating activities	1,329,991	2,922,014			
16 (a)	Reconciliation of Consolidated net operating cash flow					
	Profit after tax	161,233	(1,195,134)			
	Adjustment for non-cash items and others:					
	- Depreciation and amoritisation	1,166,407	1,161,147			
	- Provisions	537,939	658,786			
	- Share of profit of equity accounted investees	(360,063)	(209,033)			
	- Finance cost	655,099	702,226			
	- Tax Expense	(193,565)	(208,762)			
	- Contribution to WPPF	65,491	88,610			
	-Lease and other adjustments	278,277	217,363			
	Changes in:					
	- Inventories	(5,189,820)	(1,616,656)			
	- Trade and other receivables	(589,664)	(641,410)			
	- Advances, deposits and prepayments	(644,779)	(1,059,807)			
	- Trade and other payables, Employment benefits	277,770	1,646,687			
	Net cash from operating activities	(3,835,675)	(455,981)			

17 Consolidated operating segments Please see Annexure A.

	For the nine	For the nine months from			
	July 2020	July 2019			
	to	to			
	March 2021	March 2020			
Consolidated EPS, NAV per share, and NOCFPS					
Weighted average number of ordinary shares (in thousand)	63,110	63,110			
Consolidated profit attributable to equity					
holders of the Company (Taka '000)	223,146	(1,003,320)			
Earnings per share (Taka)	3.54	(15.90)			
Consolidated cash flows from operating activities					
(Taka '000)	(3,835,675)	(455,981)			
Net operating cash flows per share (NOCFPS)	(60.78)	(7.23)			
	31 March 2021	30 June 2020			
	Taka	Taka			
Consolidated net asset attributable to equity holders					
of the Company (Taka '000)	7,914,028	7,898,638			
Net asset value (NAV) per share	125.40	125.16			

18

Reasons for significant deviations: The Group achieved a decent revenue growth during the nine months period ended on 31 March 2021 which was mainly contributed by growing sales in Consumer Brands, Premiaflex, Retain Chain, Foods and Animal Health segments. Due to the growth in consolidated revenue along with decline in certain operating expenses and reduction in finance cost, consolidated profit has demonstrated a positive move compared to the SPLY. Share of the profit of equity accounted investees also contributed to the consolidated profit. The consequential results of positive consolidated profit ultimately contributed to improve consolidated EPS. NOCFPS reduced due to investing in working capital to facilitate revenue growth in coming months.

19 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

Annexure-A

Consolidated operating segments

Figures in '000' Taka For the nine months from July 2020 to March 2021

	Reportable Segment											Total	Unallocated/	
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Elimination	Total
External revenue	9,036,782	3,259,198	5,267,126	2,374,723	9,683,525	3,882,235	9,492,648	1,291,863	4,430,988	4,093,964	1,154,778	53,967,830	3,001,825	56,969,655
Inter-segment revenue	-	-	518,504	-	20,794	44,647	37,146	50,586	68,232	383,127	-	1,123,037	154,957	1,277,995
Segment revenue	9,036,782	3,259,198	5,785,630	2,374,723	9,704,319	3,926,882	9,529,794	1,342,450	4,499,220	4,477,091	1,154,778	55,090,868	3,156,782	58,247,650
Depreciation and amortisation	235,644	19,797	58,387	15,149	50,634	26,054	140,549	38,341	48,169	194,813	262,526	1,090,063	76,344	1,166,407
Operating expenses	3,857,088	673,076	1,708,372	420,817	1,225,219	205,461	1,819,109	179,659	386,620	402,046	891,718	11,769,185	299,799	12,068,984
Finance cost / (income)	81,880	80,180	19,740	89,511	202,185	(34,555)	943,092	(53,720)	222,154	344,743	623,389	2,518,600	134,464	2,653,064
Segment profit/(loss) before tax	1,718,871	265,500	(226,366)	322,556	917,494	55,057	(1,016,905)	235,348	23,088	81,569	(1,385,623)	990,591	518,269	1,508,860
Segment assets at 31 March 2021	11,003,007	2,434,680	5,365,235	2,805,341	13,381,829	1,970,484	3,981,689	2,569,189	2,570,273	6,310,586	9,544,926	61,937,239	7,525,254	69,462,493
Segment liabilities at 31 March 2021	4,675,305	1,395,789	2,530,251	1,733,602	8,494,693	808,689	17,007,757	1,144,194	4,384,821	5,765,793	12,662,228	60,603,121	653,649	61,256,770

For the nine months from July 2019 to March 2020

	Reportable segment											Total	Unallocated/	
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Elimination	Total
External revenue	8,852,918	2,702,368	3,853,558	2,006,806	9,536,906	3,687,487	8,551,798	1,514,069	3,760,684	3,062,815	1,717,158	49,246,567	2,612,579	51,859,146
Inter-segment revenue	-	-	409,921	-	3,316	28,398	23,559	49,026	35,816	190,693	-	740,728	101,880	842,608
Segment revenue	8,852,918	2,702,368	4,263,479	2,006,806	9,540,222	3,715,885	8,575,356	1,563,095	3,796,500	3,253,507	1,717,158	49,987,295	2,714,459	52,701,753
Depreciation and amortisation	243,255	22,550	60,528	24,482	46,502	24,861	164,514	39,070	47,287	192,653	206,278	1,071,980	89,167	1,161,147
Operating expenses	3,969,204	683,712	1,832,218	469,037	1,562,251	203,865	1,740,261	187,047	428,081	338,489	886,820	12,300,986	340,597	12,641,582
Finance cost / (income)	124,120	181,860	194,070	147,823	395,236	(46,482)	1,063,853	(31,109)	293,955	391,465	575,831	3,290,621	235,039	3,525,661
Segment profit/(loss) before tax	1,680,657	44,642	(752,941)	127,297	985,739	150,168	(1,156,455)	230,573	(81,765)	(305,496)	(1,451,941)	(529,522)	243,846	(285,676)
Segment assets at 30 June 2020	9,773,635	2,244,885	5,167,266	2,810,476	12,187,543	1,843,553	3,508,328	2,490,900	2,407,971	5,808,493	9,640,107	57,883,156	3,679,667	61,562,823
Segment liabilities at 30 June 2020	4,692,047	819,562	1,473,492	1,966,169	9,083,288	711,620	15,460,132	1,223,639	4,203,136	5,206,289	11,496,979	56,336,353	(2,063,507)	54,272,846